Gridsum to Announce Third Quarter 2016 Financial Results on November 21, 2016
Nov 02, 2016 12:01 pm UTC| Business
BEIJING, Nov. 02, 2016 -- Gridsum Holding Inc. (“Gridsum” or the “Company”) (NASDAQ:GSUM), a leading provider of sophisticated data analysis software in China, today announced that it plans to release its unaudited...
Gridsum to Announce Third Quarter 2016 Financial Results on November 21, 2016
Nov 02, 2016 12:01 pm UTC| Business
BEIJING, Nov. 02, 2016 -- Gridsum Holding Inc. (“Gridsum” or the “Company”) (NASDAQ:GSUM), a leading provider of sophisticated data analysis software in China, today announced that it plans to release its unaudited...
Momenta Pharmaceuticals Reports Third Quarter 2016 Financial Results
Nov 02, 2016 12:01 pm UTC| Business
--Company appoints Scott M. Storer as SVP and CFO-- --Initiates Phase 1 trial for M834, biosimilar ORENCIA® (abatacept) candidate-- CAMBRIDGE, Mass., Nov. 02, 2016 -- Momenta Pharmaceuticals,Inc. (Nasdaq:MNTA) today...
Momenta Pharmaceuticals Reports Third Quarter 2016 Financial Results
Nov 02, 2016 12:01 pm UTC| Business
--Company appoints Scott M. Storer as SVP and CFO-- --Initiates Phase 1 trial for M834, biosimilar ORENCIA® (abatacept) candidate-- CAMBRIDGE, Mass., Nov. 02, 2016 -- Momenta Pharmaceuticals,Inc. (Nasdaq:MNTA) today...
Argos Therapeutics Participating in 4th International mRNA Health Conference
Nov 02, 2016 12:01 pm UTC| Business
DURHAM, N.C., Nov. 02, 2016 -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis®...
Argos Therapeutics Participating in 4th International mRNA Health Conference
Nov 02, 2016 12:01 pm UTC| Business
DURHAM, N.C., Nov. 02, 2016 -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis®...
Nov 02, 2016 12:01 pm UTC| Business
CAMBRIDGE, Mass., HERTFORDSHIRE, England and PITTSBURGH, Nov. 02, 2016 -- Momenta Pharmaceuticals,Inc. (Nasdaq:MNTA) and Mylan N.V. (NASDAQ:MYL) (TASE:MYL), today announced that dosing has begun in a Phase 1 study to...